Summation of Precordial R Wave Amplitudes, a Clinical Parameter for Detecting Early TTR Amyloidosis Cardiac Involvement
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Maurer, M.S.; Schwartz, J.H.; Gundapaneni, B.; Elliott, P.M.; Merlini, G.; Waddington-Cruz, M.; Kristen, A.V.; Grogan, M.; Witteles, R.; Damy, T.; et al. ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N. Engl. J. Med. 2018, 379, 1007–1016. [Google Scholar] [CrossRef] [PubMed]
- Porcari, A.; Bussani, R.; Merlo, M.; Varrà, G.G.; Pagura, L.; Rozze, D.; Sinagra, G. Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination. Front. Cardiovasc. Med. 2021, 8, 749523. [Google Scholar] [CrossRef] [PubMed]
- Lindmark, K.; Pilebro, B.; Sundström, T.; Lindqvist, P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 2021, 8, 745–749. [Google Scholar] [CrossRef]
- González-López, E.; Gallego-Delgado, M.; Guzzo-Merello, G.; Moral, F.J.D.H.-D.; Cobo-Marcos, M.; Robles, C.; Bornstein, B.; Salas, C.; Lara-Pezzi, E.; Alonso-Pulpon, L.; et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 2015, 36, 2585–2594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ladefoged, B.; Dybro, A.; Povlsen, J.A.; Vase, H.; Clemmensen, T.S.; Poulsen, S.H. Diagnostic delay in wild type transthyretin cardiac amyloidosis-A clinical challenge. Int. J. Cardiol. 2020, 304, 138–143. [Google Scholar] [CrossRef] [PubMed]
- Hanna, M.; Ruberg, F.L.; Maurer, M.S.; Dispenzieri, A.; Dorbala, S.; Falk, R.H.; Hoffman, J.; Jaber, W.; Soman, P.; Witteles, R.M.; et al. Cardiac Scintigraphy with Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 2020, 75, 2851–2862. [Google Scholar] [CrossRef] [PubMed]
- Martinez-Naharro, A.; Treibel, T.A.; Abdel-Gadir, A.; Bulluck, H.; Zumbo, G.; Knight, D.S.; Kotecha, T.; Francis, R.; Hutt, D.F.; Rezk, T.; et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J. Am. Coll. Cardiol. 2017, 70, 466–477. [Google Scholar] [CrossRef]
- Rapezzi, C.; Quarta, C.C.; Guidalotti, P.L.; Pettinato, C.; Fanti, S.; Leone, O.; Ferlini, A.; Longhi, S.; Lorenzini, M.; Reggiani, L.B.; et al. Role of (99m) Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc. Imaging 2011, 4, 659–670. [Google Scholar] [CrossRef] [Green Version]
- Gillmore, J.D.; Damy, T.; Fontana, M.; Hutchinson, M.; Lachmann, H.J.; Martinez-Naharro, A.; Quarta, C.C.; Rezk, T.; Whelan, C.J.; Gonzalez-Lopez, E.; et al. A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 2018, 39, 2799–2806. [Google Scholar] [CrossRef] [PubMed]
- Grogan, M.; Scott, C.G.; Kyle, R.A.; Zeldenrust, S.R.; Gertz, M.A.; Lin, G.; Klarich, K.W.; Miller, W.L.; Maleszewski, J.J.; Dispenzieri, A. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J. Am. Coll. Cardiol. 2016, 68, 1014–1020. [Google Scholar] [CrossRef] [PubMed]
- Cappelli, F.; Vignini, E.; Martone, R.; Perlini, S.; Mussinelli, R.; Sabena, A.; Morini, S.; Gabriele, M.; Taborchi, G.; Bartolini, S.; et al. Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Circ. Heart Fail. 2020, 13, e006619. [Google Scholar] [CrossRef] [PubMed]
- Cheng, Z.; Kang, L.; Tian, Z.; Chen, W.; Guo, W.; Xu, J.; Chen, T.; Fang, L.; Zeng, Y.; Cheng, K.; et al. Utility of combined indexes of electrocardiography and echocardiography in the diagnosis of biopsy proven primary cardiac amyloidosis. Ann. Noninvasive Electrocardiol. 2011, 16, 25–29. [Google Scholar] [CrossRef] [PubMed]
- DePace, N.L.; Colby, J.; Hakki, A.H.; Manno, B.; Horowitz, L.N.; Iskandrian, A.S. Poor R wave progression in the precordial leads: Clinical implications for the diagnosis of myocardial infarction. J. Am. Coll. Cardiol. 1983, 2, 1073–1079. [Google Scholar] [CrossRef] [Green Version]
- Cyrille, N.B.; Goldsmith, J.; Alvarez, J.; Maurer, M.S. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am. J. Cardiol. 2014, 114, 1089–1093. [Google Scholar] [CrossRef] [PubMed]
- Zhao, L.; Li, J.; Tian, Z.; Fang, Q. Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. J. Cardiol. 2016, 68, 426–430. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, D.; Lee, G.Y.; Choi, J.O.; Kim, K.; Kim, S.J.; Jeon, E.S. Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis. Sci. Rep. 2019, 9, 7746. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruberg, F.L.; Berk, J.L. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012, 126, 1286–1300. [Google Scholar] [CrossRef] [Green Version]
- Augusto, J.B.; Johner, N.; Shah, D.; Nordin, S.; Knott, K.D.; Rosmini, S.; Lau, C.; Alfarih, M.; Hughes, R.; Seraphim, A.; et al. The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage. Eur. Heart J. Cardiovasc. Imaging 2021, 22, 790–799. [Google Scholar] [CrossRef]
- Koike, H.; Ikeda, S.; Takahashi, M.; Kawagashira, Y.; Iijima, M.; Misumi, Y.; Ando, Y.; Ikeda, S.I.; Katsuno, M.; Sobue, G. Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology 2016, 87, 2220–2229. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Isotani, Y.; Amiya, E.; Ishida, J.; Komuro, I. Summation of Precordial R Wave Amplitudes, a Clinical Parameter for Detecting Early TTR Amyloidosis Cardiac Involvement. J. Cardiovasc. Dev. Dis. 2022, 9, 348. https://doi.org/10.3390/jcdd9100348
Isotani Y, Amiya E, Ishida J, Komuro I. Summation of Precordial R Wave Amplitudes, a Clinical Parameter for Detecting Early TTR Amyloidosis Cardiac Involvement. Journal of Cardiovascular Development and Disease. 2022; 9(10):348. https://doi.org/10.3390/jcdd9100348
Chicago/Turabian StyleIsotani, Yoshitaka, Eisuke Amiya, Junichi Ishida, and Issei Komuro. 2022. "Summation of Precordial R Wave Amplitudes, a Clinical Parameter for Detecting Early TTR Amyloidosis Cardiac Involvement" Journal of Cardiovascular Development and Disease 9, no. 10: 348. https://doi.org/10.3390/jcdd9100348
APA StyleIsotani, Y., Amiya, E., Ishida, J., & Komuro, I. (2022). Summation of Precordial R Wave Amplitudes, a Clinical Parameter for Detecting Early TTR Amyloidosis Cardiac Involvement. Journal of Cardiovascular Development and Disease, 9(10), 348. https://doi.org/10.3390/jcdd9100348